Quantitative trait loci, genes, and polymorphisms that regulate bone mineral density in mouse  by Xiong, Qing et al.
Genomics 93 (2009) 401–414
Contents lists available at ScienceDirect
Genomics
j ourna l homepage: www.e lsev ie r.com/ locate /ygenoReview
Quantitative trait loci, genes, and polymorphisms that regulate bone mineral density
in mouse
Qing Xiong a,d, Yan Jiao a, Karen A. Hasty a, S. Terry Canale a, John M. Stuart b, Wesley G. Beamer c,
Hong-Wen Deng e, David Baylink f, Weikuan Gu a,⁎
a Department of Orthopaedic Surgery — Campbell Clinic and Pathology, University of Tennessee Health Science Center, Memphis, TN 38163, USA
b Department of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA
c The Jackson Laboratory, Bar Harbor, ME 04609, USA
d Department of Computer Science and Technology, Southwest University, Chongqing 400715, PR China
e Departments of Orthopedic Surgery and Basic Medical Sciences, University of Missouri — Kansas City, Kansas City, MO 64110, USA
f Department of Medicine, Loma Linda University, Loma Linda, CA 92350, USA⁎ Corresponding author. University of Tennessee Heal
E-mail addresses: qxiong1@utmem.edu (Q. Xiong), y
(J.M. Stuart), wesley.beamer@jax.org (W.G. Beamer), de
0888-7543/$ – see front matter © 2008 Elsevier Inc. A
doi:10.1016/j.ygeno.2008.12.008a b s t r a c ta r t i c l e i n f oArticle history: This is an in silico analysi
Received 21 August 2008
Accepted 15 December 2008
Available online 14 January 2009
Keywords:
BMD
QTL
Gene
Polymorphism
Mouses of data available from genome-wide scans. Through analysis of QTL, genes
and polymorphisms that regulate BMD, we identiﬁed 82 BMD QTL, 191 BMD-associated (BMDA) genes,
and 83 genes containing known BMD-associated polymorphisms (BMDAP). The catalogue of all BMDA/
BMDAP genes and relevant literatures are provided. In total, there are substantially more BMDA/BMDAP
genes in regions of the genome where QTL have been identiﬁed than in non-QTL regions. Among 191
BMDA genes and 83 BMDAP genes, 133 and 58 are localized in QTL regions, respectively. The difference
was still noticeable for the chromosome distribution of these genes between QTL and non-QTL regions.
These results have allowed us to generate an integrative proﬁle of QTL, genes, polymorphisms that
determine BMD. These data could facilitate more rapid and comprehensive identiﬁcation of causal genes
underlying the determination of BMD in mouse and provide new insights into how BMD is regulated in
humans.
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Osteoporosis is a multifactorial bone disease affecting millions
of people around the world. One of the major determinants of risk
for bone fracture in individuals with osteoporosis is bone mineral
density (BMD). BMD is a quantitative trait regulated by complex
interactions of genetic and environmental factors [1]. BMD is
largely inheritable with twin and family studies showing that
genetic factors may account for 50–80% of the variance in BMD [2–
4]. Accumulating evidence indicated that BMD is under the control
of multiple genes, each with modest effects [3–5]. In order to
determine the genetic components underlying BMD variation, many
investigators have performed breeding studies to identify quanti-
tative trait loci (QTL). Using mouse models they have established
the location of a large number of QTL. However, the identiﬁcation
of the genes responsible for these QTL remains a major challenge
[6]. Since standard QTL mapping results in identiﬁcation of large
regions which may include up to hundreds of genes, it has proven
difﬁcult to establish which genes are responsible for the QTL from
such large segments of chromosomes (Chr). One approach to this
problem is to generate congenic sublines to reduce the size of the
linked region [7]. Because this is an expensive and time consuming
approach, only few genes have been identiﬁed as causal genes of
BMD QTL [8–11].
Decades of research on molecular biology and genetics has
accumulated tremendous amount of data related to gene function.
The completion of the mouse genome sequence and advances in
genome annotation has shown that many genes are associated with
BMD in a variety of populations or species. However, it is still a
challenge to integrate those data from gene function analysis into a
comprehensive understanding of how genes are related to BMD. In
this review, we systematically examine the possible involvement of
every known gene in BMD regulation over the whole mouse genome
according to the literature information from PubMed (http://www.
ncbi.nlm.nih.gov/pubmed/) and Online Mendelian Inheritance in
Man (OMIM, http://www.ncbi.nlm.nih.gov/omim/), as well as the
information from Mammalian Phenotype Ontology (http://www.
informatics.jax.org/searches/MP_form.shtml) and Gene Ontology
(http://www.informatics.jax.org/searches/GO_form.shtml). We
have established the distribution of BMD-associated (BMDA) genes
and those genes containing known BMD-associated polymorphisms
(BMDAP) within regions of the chromosome where QTL have been
identiﬁed. Those data permits an alternative approach to determina-
tion of the genes which are the most important candidates for
regulating BMD and the association of these genes with BMD QTL.
Our aim was to bridge the gap between QTL analysis and genome
annotation, and generate an integrative proﬁle of QTL, genes and
polymorphisms that regulate BMD over whole mouse genome.
These data will be a valuable source for BMD QTL studies, and willfacilitate more rapid and comprehensive identiﬁcation of genes
underlying BMD QTL.
Materials and methods
Identiﬁcation of QTL
A literature search using PubMed was conducted with key words
“Bone” and “QTL” for every publication up to January 2008. A total of
82 BMD QTL were identiﬁed (Table 1). For well-deﬁned QTL, the
ﬂanking markers provided by the authors were used to establish the
limits of the QTL region. For other QTL, the 2-LOD support interval,
the chromosomal region in which the QTL is located with a
conﬁdence of ∼95%, was used to establish the limits of the QTL
region. For those QTL in which neither ﬂanking markers nor
information of 2-LOD support interval was not available, a genomic
region containing 20 mega base pairs (Mbp) on each side of the peak
marker was considered as the QTL region. We assumed that 20 Mbp
on each side of the peak marker would be adequate to encompass the
underlying genes or polymorphisms responsible for the QTL. Several
QTL have been dissected into multiple linked sub-loci. For the
purposes of our analysis, we list those sub-loci as independent QTL to
allow investigators to better compare and evaluate them. It is possible
that our search method was insufﬁcient to collect every relevant
publication or QTL.
Identiﬁcation of genes
We systematically evaluated the potential involvement of every
gene in BMD variation over the whole mouse genome with all
available reports in PubMed, OMIM, Mammalian Phenotype Ontology,
and Gene Ontology. To accomplish this, we obtained the genes for
every chromosome and QTL from the Ensembl database (Release 48);
then we searched PubMed and OMIM to get a preliminary list of
candidate genes associated with BMD. The search terms were the
combination of the symbol of the gene and BMD/bone mineral
density. We performed the searching using PGMapper, software
which we have recently developed [12]. Next, we obtained another
preliminary list of candidate genes by searching Mammalian Pheno-
type Ontology and Gene Ontology with key words “abnormal bone
mineralization” and “bone mineralization”, respectively. Finally we
hand curated the associated literature to determine the actual
connection between those preliminary candidate genes and BMD.
We considered a gene to be a BMDA gene if it was associated with
BMD by at least one of the following criteria: 1) established by
functional studies such as knockouts, transgenics, mutagenesis, RNA
interference, etc.; 2) identiﬁed in association studies; and 3) identiﬁed
in clinical studies. Many BMDA genes were identiﬁed in human
studies. We included the mouse homologues of these human genes in
Table 1
The information of QTL of bone mineral density in mouse
QTL Chr Markers Search region (bp) BMDA genes within QTL BMDAP genes within QTL
Bmd1 [13,14] 1 D1Mit135–D1Mit17 107206163–191395299 Darc[8], Tnfrsf11a[15], Il10[16], Adipor1[17],
Fasl[18], Ddr2[19], Ptgs2[20]
Darc[8], Tnfrsf11a[15], Il10[16]
Bmd5 [13,21] 1 D1Mit282–D1Mit511 73273629–193992345 Darc[8], Tnfrsf11a[15], Il10[16],Inpp5d (Ship)[22],
Adipor1[17], Fasl[18], Inha[23], Ddr2[19],
Pax3[24], Ihh[25], Ptgs2[20]
Darc[8], Tnfrsf11a[15], Il10[16]
Beamer et al. [26] 1 rs30595455–rs6197487 175298492–175438719
Beamer et al. [26] 1 D1Mit111–rs3710340 170937673–173868197 Ddr2[19]
Beamer et al. [26] 1 rs3710340–D1Kls6–
1(rs30595455)
173868197–175298492 Darc[8] Darc[8]
Bmd19 [13] 1 D1Mit282–-aD1Mit416
(D1Mit441)
73273629–115780992 Darc[8], Tnfrsf11a[15], Inpp5d (Ship)[22],
Inha[23], Pax3[24], Ihh[25]
Darc[8], Tnfrsf11a[15]
Bmd22 [27] 1 D1Mit115 159610205–197195432 Darc[8], Plxna2[28], Fasl[18], Ddr2[19] Darc[8], Plxna2[28]
BMD1–1 [29] 1 D1Mit30–D1Mit453 135259675–167119780 Adipor1[17], Fasl[18], Ptgs2[20]
BMD1–2 [29] 1 D1Mit113–D1Mit150 173734611–176559001 Darc[8] Darc[8]
BMD1–3 [29] 1 D1Mit221–D1Mit511 187046266–193992345
Klein et al. [30] 1 D1Mit291 166554196–197195432 Darc[8], Plxna2[28], Ddr2[19] Darc[8], Plxna2[28]
Masinde et al. [31] 1 D1Mit33 140335734–180335833 Darc[8], Fasl[18], Ddr2[19], Ptgs2[20] Darc[8]
Masinde et al. [31] 1 D1Mit362 171074792–197195432 Darc[8], Plxna2[28], Ddr2[19] Darc[8], Plxna2[28]
Klein et al. [32] 1 Cfh 121982432–162079988 Il10[16], Adipor1[17], Ptgs2[20] Il10[16]
Masinde et al. [31] 1 D3Mit217 45355605–85355731 Pthr1(Pth1r)[33,34], Stat1[35], Inha[23], Igfbp5[36],
Mstn(Gdf8) [37], Pax3[24], Ihh[25], Satb2[38]
Pthr1[33,34]
Bmd6 [21] 2 D2Mit456 148761877–188761999 Ncoa3[39], Mmp9[40], Cst10[41] Ncoa3[39], Mmp9[40]
Benes et al. [42] 2 D2Mit312 0–23152509
Benes et al. [42] 2 D2Mit119 (D2Mit118)a 0–32115535 Qrfp[42–44], Abo[45] Qrfp[42–44]
Benes et al. [42] 2 D2Mit464 0–38517461 Qrfp[42–44], Abo[45] Qrfp[42–44]
Benes et al. [42] 2 D2Mit296 11180075–51180221 Qrfp[42–44], Abo[45] Qrfp[42–44]
Bdt1 [46] 2 D2Mit413 146972482–186972598 Mmp9[40], Ncoa3[39], Cst10[41] Mmp9[40], Ncoa3[39]
Klein et al. [30] 2 D2Mit94 60015767–100015926 Acp2(Lap)[47], Sp3[48]
Masinde et al. [31] 2 D2Mit62 97938185–137938345 Bmp2[49,50], Cat[51], Traf6[52,53], Hdc[54],
Duox2[55], Grem1[56]
Bmp2[49,50], Cat[51], Traf6[52,53]
Masinde et al. [31] 2 D2Mit263 142180682–182180793 Mmp9[40], Ncoa3[39], Cst10[41] Mmp9[40], Ncoa3[39]
Klein et al. [32] 2 Il2ra 0–31614818 Abo[45]
Klein et al. [32] 2 Iapls2–4 (D2Mit285)a 132683037–172683177 Bmp2[49,50], Mmp9[40], Ncoa3[39], Cst10[41] Bmp2[49,50], Mmp9[40], Ncoa3[39]
Bmd17 [13] 3 D3Mit221–D3Mit133 7891493–43786906 Fgf2[57]
Bdt2 [46] 3 D3Mit14 111693820–151693987 Dkk2[58], Hs2st1[59]
Bmd7 [13,21] 4 D4Mit27–D4Mit42 88709736–150944202 Mthfr[60,61], Tnfrsf1b[62–64], Plod1[65],
Nppb[66], Cnr2[67], Gja4[67], Lepr[68],
Matn1[69], Hspg2[70]
Mthfr[60,61], Tnfrsf1b[62–64],
Plod1[65], Nppb[66], Cnr2[67],
Gja4[67], Lepr[68]
Klein et al. [30] 4 D4Mit312 121449885–161449991 Mthfr[60,61], Tnfrsf1b[62–64], Plod1[65],
Nppb[66], Cnr2[67], Gja4 [67], Hspg2[70]
Mthfr[60,61], Tnfrsf1b[62–64],
Plod1[65], Nppb[66], Cnr2[67],
Gja4 [67]
Masinde et al. [31] 4 D4Mit204 112983282–152983386 Mthfr[60,61], Tnfrsf1b[62–64], Plod1[65],
Nppb[66], Cnr2[67], Gja4 [67], Hspg2[70]
Mthfr[60,61], Tnfrsf1b[62–64],
Plod1[65], Nppb[66], Cnr2[67],
Gja4 [67]
Masinde et al. [31] 4 D4Mit214 25671314–65671438 Ptpn3[71]
Koller et al. [72] 4 D4Mit124 103992565–143992719 Cnr2[67], Gja4 [67], Hspg2[70] Cnr2[67], Gja4 [67]
Bmd2 [13,14] 5 D5Mit148–D5Mit161 32278263–127404378 Kit[73], Cd38[74], Aldh2[75], Sult1e1[76],
Mepe[77], Fgfr3[78], Ibsp(Bsp)[79], Fosl2[80],
Gc(Dbp)[81], Bmp2k[82], P2rx7[20]
Kit[73], Cd38[74], Aldh2[75],
Sult1e1[76]
Bmd8 [13,21] 6 D6Mit93–D6Mit150 52111712–116105285 Mitf[83], Pparg[84], Ggcx[85], Eif2ak3[86] Mitf[83], Pparg[84], Ggcx[85]
Bmd20 [27] 6 D6Mit209 55494350–95494483 Ggcx[85], Eif2ak3[86] Ggcx[85]
Bdt3 [46] 6 D6Mit198 (D6Mit259)a 122693035–162693150 Mgp[87], Lrp6[88], Fgf23[89], Pthlh[90],
Sox5[91]
Mgp[87]
Bmd9 [21,27] 7 D7Mit300 77953392–117953516 Plin[92] Plin[92]
Benes et al. [42] 7 D7Mit210 10648941–50649028 Tgfb1[93–95], Apoe[96], Ercc2[97] Tgfb1[93–95], Apoe[96]
Benes et al. [42] 7 D7Mit227 17365609–57365698 Tgfb1[93–95], Apoe[96], Nell1[98] Tgfb1[93–95], Apoe[96]
Bdt4 [46] 7 D7Mit80 27494518–67494662 Nell1[98]
Klein et al. [32] 7 D7Mit234 73179294–113179422 Plin[92], Igf1r[99] Plin[92]
Bmd10 [21] 9 D9Mit196 65791117–105791259 Lipc[67] Lipc[67]
Masinde et al. [31] 9 D9Mit270 55964912–95965059 Cyp1a1[100,101], Sema7a[102], Lipc[67],
Smad3[103], Glce[104], Cd276 (B7–H3)[105]
Cyp1a1[100,101], Sema7a[102],
Lipc[67]
Masinde et al. [31] 9 D9Mit90 12308040–52308179 Icam1[67] Icam1[67]
Bmd21 [27] 10 D10Mit35 101642455–141642679 Cyp27b1[106]
Yu et al. [107] 10 D10Mit31 47718408–87718557 Igf1[108,109], Itgb2 (Cd18)[110],
Col13a1[111], Egr2[112], Gna11[113]
Igf1[108,109]
Bmd11 [13,21] 11 D11Mit71–D11Mit320 6830280–70766988 Alox15[9,114], Alox12[115,116], Pdlim4
(Ril)[117], Shbg[118], Sparc[119]
Alox15[9,114], Alox12[115,116],
Pdlim4 (Ril)[117], Shbg[118]
Benes et al. [42] 11 D11Mit284 68990137–108990222 Alox15[9,114], Alox12[115,116], Gh[120,121],
Shbg[118], Col1a1[93,122], Ace[123],
Sost[124], Nog[125], Nf1[126], Dlx3[127],
Nos2[128], Thra[129]
Alox15[9,114], Alox12[115,116],
Gh[120,121], Shbg[118],
Col1a1[93,122], Ace[123],
Sost[124]
Benes et al. [42] 11 D11Mit160 76756413–116756606 Gh[120,121], Col1a1[93,122], Ace[123],
Sost[124], Nog[125], Nf1[126], Dlx3[127],
Nos2[128], Thra[129], Sox9[130]
Gh[120,121], Col1a1[93,122],
Ace[123], Sost[124]
(continued on next page)
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Table 1 (continued)
QTL Chr Markers Search region (bp) BMDA genes within QTL BMDAP genes within QTL
Pbd1 [131] 11 D11Mit90–D11Mit59 70313264–100006162 Col1a1[93,122], Nog[125], Nf1[126],
Dlx3[127], Nos2[128], Thra[129]
Col1a1[93,122]
Klein et al. [30] 11 D11Mit349 35602850–75602967 Alox15[9,114], Pdlim4 (Ril)[117],
Shbg[118], Sparc[119]
Alox15[9,114], Pdlim4 (Ril)[117],
Shbg[118]
Masinde et al. [31] 11 D11Mit36 63658789–103659021 Alox15[9,114], Alox12[115,116],
Col1a1[93,122], Shbg[118], Sost[124],
Nog[125], Nf1[126], Dlx3[127],
Nos2[128], Thra[129]
Alox15[9,114], Alox12[115,116],
Col1a1[93,122], Shbg[118], Sost[124]
Klein et al. [32] 11 D11Mit14 78544969–118545124 Gh[120,121], Col1a1[93,122], Ace[123],
Sost[124], Nog[125], Nf1[126], Dlx3[127],
Nos2[128], Thra[129], Sox9[130]
Gh[120,121], Col1a1[93,122],
Ace[123], Sost[124]
Bmd12 [21] 12 D12Mit215 0–27619503 Matn3[69]
Masinde et al. [31] 12 D12Mit201 53392448–93392662 Esr2[132,133], Tshr[134,135] Esr2[132,133], Tshr[134,135]
Bmd3 [13,14] 13 D13Mit205–D13Mit165 6077006–44311123 Sfrp4[10,136,137], Hfe[138], Gli3[139] Sfrp4[10,136,137], Hfe[138],
Bmd13 [13,21] 13 D13Mit245–D13Mit13 45159272–56582945 Ror2[140] Ror2[140]
Benes et al. [42] 13 D13Mit20 35673906–75674065 Ror2[140], Ptch1[141] Ror2[140]
Pbd2 [131] 13 D13Mit174–D13Mit135 17106757–22018222 Sfrp4[10,136,137] Sfrp4[10,136,137]
Bmd14 [21] 14 D14Mit160(D14Mit192)a 52317211–92317472 Tnfsf11[142,143], Lect1(Chm1)[144],
Gulo[145], Mmp14[146], Ift88[147]
Tnfsf11[142,143]
Bmd18 [13] 14 D14Mit203 (D14Mit123)–
D14Mit227a
66836813–82881419 Tnfsf11[142,143], Lect1(Chm1)[144] Tnfsf11[142,143]
Masinde et al. [31] 14 D14Mit194 74235479–114235570 Tnfsf11[142,143], Lect1(Chm1)[144] Tnfsf11[142,143]
Klein et al. [32] 14 Ptprg (12386046–13074555) 0–33074555 Flnb[148], Thrb[149]
Koller et al. [72] 14 D14Mit166 (D14Mit167)a 104214398–126214528
Bmd4 [13,14] 15 D15Mit115–D15Mit159 56154867–87295645 Ly6a[150], Atf4[151]
Bdt5 [46] 15 D15Mit13 0–23410347 Ghr[152]
Bdt6 [46] 15 D15Mit206 22263956–62264078 Ext1[153], Tnfrsf11b[142,154],
Tm7sf4 (Dcstamp)[155], Ank[156],
Klf10(Tieg1)[157]
Ext1[153], Tnfrsf11b[142,154]
Masinde et al. [31] 15 D15Mit179 0–33419824 Ghr[152], Ank[156]
Klein et al. [32] 15 Atf4 60085614–100087970 Vdr[158–161], Wnt10b[162],
Ly6a[150], Atf4[151]
Vdr[158–161]
Yu et al. [107] 15 D15Mit115 36154867–76155009 Ext1[153], Tnfrsf11b[142,154], Tm7sf4
(Dcstamp)[155], Klf10(Tieg1)[157], Ly6a[150]
Ext1[153], Tnfrsf11b[142,154]
Bmd15 [21] 16 D16Mit12 19118134–59118325 Casr[163], Ahsg[164], Ostn[165] Casr[163], Ahsg[164]
Benes et al. [42] 16 D16Mit100 0–32095407 ComtComt1[166,167], Ahsg[164], Ostn[165] Comt[166,167], Ahsg[164],
Benes et al. [42] 16 D16Mit39 23457588–63457715 Casr[163], Ostn[165] Casr[163]
Klein et al. [32] 16 Hmg1-rs7 (D16Mit102)a 3963612–43963740 Casr[163], Comt[166,167], Ahsg[164],
Ostn[165]
Casr[163], Comt[166,167],
Ahsg[164],
Masinde et al. [31] 17 D17Mit175 11571388–51571496 Tnf[168,169], Runx2[170,171], Clcn7[172],
Ager (Rage)[173], Pkd1[174], Ddr1[175]
Tnf[168,169], Runx2[170,171],
Clcn7[172],
Masinde et al. [31] 17 D17Mit176 22877243–62877410 Tnf[168,169], Runx2[170,171], Clcn7[172],
Ager (Rage)[173], Pkd1[174], Ddr1[175]
Tnf[168,169], Runx2[170,171],
Clcn7[172],
Bmd16 [13,21] 18 D18Mit120–D18Mit124 36214168–57617290
Masinde et al. [31] 18 D18Mit152 42096421–82096560 Smad4[176], Csf1r[177], Adrb2[178]
Klein et al. [32] 18 D18Ncvs23 (D18Mit221)a 0–30034034
Klein et al. [32] 19 D19Ncvs21 (D19Mit105)a 37203551–77203640 Cyp17a1[179], Chuk(Ikk-alpha)[180] Cyp17a1[179]
Parsons et al. [181] X Car5b–Asb11 160414754–160897102
a The marker is not mapped to the assembly in the current Ensembl database; alternatively, we chose a marker near the target marker for gene searching. The information of
distance between those two markers is from MGI, The Jackson Laboratory.
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Distribution of BMDA genes between QTL regions and
non-QTL regions
We identiﬁed 191 BMDA genes within the whole mouse genome.
Among them,133 (approximately 70%) were located in regions known
to contain QTL for BMD. The catalogue of all BMDA genes and relevant
literature establishing their candidacy can be found in Supplemental
Table 1. In total, there are substantially more BMDA genes in QTL
regions than in non-QTL regions. To investigate if this is also true at the
chromosomal level, we examined the distribution of the BMDA genes
for every chromosome. Fig. 1 shows the distribution of these genes
between QTL and non-QTL regions for each chromosome. We found
that for most chromosomes there were substantially more BMDA
genes in QTL regions compared to non-QTL regions conﬁrming our
whole chromosome analysis. The QTL regions included all known
BMDA genes on Chr2, Chr4, Chr11, Chr12, and Chr18. In addition there
were more BMDA genes in QTL than in non-QTL regions on 10
chromosomes, including Chr1, Chr5, Chr6, Chr7, Chr10, Chr13, Chr14,Chr15, Chr16, and Chr17. There was no difference for Chr3 and Chr9.
No QTL have been identiﬁed on Chr8 and ChrY. Only two chromo-
somes, namely Chr19 and ChrX, included fewer BMDA genes in QTL
regions as compared to non-QTL regions.
Distribution of BMDAP genes between QTL regions and
non-QTL regions
We identiﬁed 83 genes containing BMD-associated polymorph-
isms (BMDAP) either in coding or regulatory regions, most of which
fell within regions of the genome containing known QTL. Among 83
BMDAP genes, 58 (approximately 70%) were located in QTL regions, a
proportion similar to that of BMDA genes. We also examined the
distribution of these genes between QTL and non-QTL region for each
chromosome (Fig. 2). The list of all BMDAP genes and the references
establishing their candidacy can be found in Supplemental Table 1.
Consistent with the results for BMDA genes, there are substantially
more BMDAP genes in QTL regions than in non-QTL regions on most
chromosomes. On Chr1, Chr2, Chr4, Chr11, Chr12, Chr15, and Chr16, all
BMDAP genes are located within QTL regions. More BMDAP genes are
found in QTL regions than in non-QTL regions on Chr5, Chr6, Chr9,
Fig. 1. Distribution of BMDA genes between QTL and non-QTL regions on each chromosome.
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Excluding Chr18 and ChrY that have no known BMDAP genes, as well
as chromosomes that have no known BMD QTL, only four chromo-
somes, namely Chr3, Chr8, Chr19, and ChrX, have fewer BMDAP genes
in QTL regions compared to non-QTL regions.
Genes containing known BMD-associated polymorphisms
Chromosome 1
Chromosome 1 contains 15 BMD QTL (Table 1) [13,14,21,26,27,29–
32], of which Bmd5 has been later dissected into several sub-loci by
two independent investigations [26,29]. Five genes containing
polymorphisms associated with BMD are located on this chromo-
some: (1) duffy antigen receptor for chemokines (Darc), (2) receptor
activator of NF-kappa-B (Rank, also named Tnfrsf11a), (3) plexin A2
(Plxna2), (4) parathyroid hormone type 1 receptor (Pthr1), and (5)
interleukin 10 (Il10). Most QTL harbor an important BMDAP gene,
Darc, which has been identiﬁed as a QTL gene underlying QTL
BMD1–2. By comparing the Darc gene sequence of low BMD C57BL/6J
(B6) and high BMD CAST/EiJ (CAST) mice with another high BMD
strain, namely C3H/HeJ (C3H), Edderkaoui et al. [8] found that the six
SNPs in the coding region were conserved in both CAST and C3H,
suggesting that one or more of these SNPs could contribute to the high
BMD phenotype exhibited by CAST and C3H mice. Further functional
analysis indicated that Darc is a negative regulator of osteoclasts and
that bone resorption is reduced in the absence of Darc, resulting in
increased BMD. Another two BMDAP genes within QTL regions are
Rank and Plxna2. In a large-scale study of postmenoparsal women,
Koh et al. [15] found that the +34863GNA and +35928insdelC
polymorphisms in intron 6 of RANK gene were signiﬁcantly associated
with the BMD of the lumbar spine (LS). The levels of BMD in
individuals bearing a minor homozygous genotype (A/A of
+34863GNA and del/del of +35928Cinsdel) were signiﬁcantly
lower than in individuals bearing other genotypes. Polymorphisms
within PLXNA2 have also been associated with BMD abnormalities by
Hwang et al. [28] These investigators selected 10 polymorphisms in
PLXNA2 for association studies in postmenopausal women. The resultsFig. 2. Distribution of BMDAP genes between QTLrevealed that the subjects carrying the minor homozygote genotype
(AA) of +14GNA tended to have higher LS BMD compared with those
carrying the major homozygote alleles or heterozygote alleles, while
the subjects carrying the minor homozygote genotype (TT) of
+183429CNT tended to have lower LS BMD.
Two BMDAP genes, Pthr1 and Il10, are located outside of QTL
region. PTHR1 has been associated with BMD by Scillitani et al. [33]
who demonstrated that the subjects bearing at least one (AAAG)6
allele in the P3 promoter of PTHR1 gene have a higher femoral neck
(FN) BMD than those without, suggesting the variation in promoter
activity of the PTHR1 gene may exert a relevant genetic inﬂuence on
BMD. IL10 has been found to be associated with BMD by Park et al.
[16]. The investigators studied the possible associations of genetic
variants in ﬁve-candidate genes with spinal BMD. Among them, IL10
−592ANC and/or IL10 ht2 were associated with decreased bone
mass. The levels of spinal BMD in individuals bearing the IL10−592CC
genotype were lower than those in others, and the BMD of IL10 ht2
bearing individuals were also lower than those in others.
Chromosome 2
Eleven BMD QTL have been identiﬁed on Chromosome 2 (Table 1)
[21,30–32,42,46]. A total of six BMDAP genes were found: (1) bone
morphogenetic protein 2 (Bmp2), (2) tumour necrosis factor receptor-
associated factor 6 (Traf6), (3) matrix metalloproteinase-9 (Mmp9),
(4) pyroglutamylated RFamide peptide (Qrfp), (5) Catalase (Cat), and
(6) nuclear receptor coactivator-3 (Ncoa3). All of the BMDAP genes on
this chromosome are contained within QTL regions. BMP2 has been
implicated to be a major risk factor for osteoporosis as well as low
BMD in an association analysis [50]. Three variants of BMP2 gene, a
missense polymorphism and two anonymous single nucleotide
polymorphism haplotypes, have been associated with osteoporosis
in the Icelandic patients. In another cross-sectional study, signiﬁcant
associations were observed between BMP2 c.584GNA, c.893TNA
genotypes and differences in BMD for males at the calcaneus as well
as females at the distal radius. Menwith BMP2 c.893 AA genotype had
a 16% higher BMD at the calcaneus, whereas women with this
genotype had a 7% lower BMD at the distal radius than the otherand non-QTL regions on each chromosome.
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associated with low bone mass in female distal radius [49].
Yamada et al. [40] examined the association of BMD with a
−1562C→T polymorphism in the promoter of the MMP9. BMD at
various sites was signiﬁcantly lower in the combined group of men
with the CT or TT genotypes or in men with the CT genotype than in
those with the CC genotype. However, no signiﬁcant differences in
BMD among MMP9 genotypes were observed in premenopausal or
postmenopausal women. These data may indicate −1562C→T
polymorphism inﬂuences on BMD variation in a sex-speciﬁc fashion.
Chromosome 3
Two BMDQTL are located on Chromosome 3 (Table 1) [13,46]. Only
one BMDAP gene in non-QTL region was found. C/A polymorphism
(rs2297480) in the promoter of Farnesyl diphosphate synthase (FDPS)
has been associated with BMD in postmenopausal elderly women. The
presence of C allele contributes to signiﬁcant reductions in bone
mineral density. The majority of skeletal sites showed the lowest BMD
with the CC and CA genotypes and the highest BMD with the AA
genotype. In silico analysis of this polymorphism reveals that the A
allele may create a binding site for Runx1, which may decrease
osteoclast activity by inhibiting FDPS transcription [182].
Chromosome 4
Chromosome 4 contains ﬁve BMD QTL (Table 1) [13,21,30,31,72].
We identiﬁed 7 BMDAP genes and all of them are located within QTL
regions, including: (1) methylenetetrahydrofolate reductase (Mthfr),
(2) tumor necrosis factor receptor superfamily member 1B (Tnfrsf1b),
(3) procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1 (Plod1), (4)
brain natriuretic peptide (Bnp, also named Nppb), (5) cannabinoid
receptor 2 (Cnr2), (6) gap junction protein alpha-4 (Gja4), and (7)
leptin receptor (Lepr). A common MTHFR C677T polymorphism has
been associated with BMD in postmenopausal Danish women [60].
The less common genotype TT was associated with signiﬁcantly lower
BMD at the femoral neck, total hip and spine. This polymorphism is
also associated with low BMD in Japanese women [61]. Two studies
have shown evidence of an association between BMD and haplotypes
deﬁned by polymorphisms at positions 593, 598 and 620 in TNFRSF1B
3′ untranslated region. In one study, an association was observed
between LS BMD and the A593-G598-T620 (AGT) haplotype [64],
whereas another larger study showed an association between FN BMD
and the A593-T598-C620 (ATC) haplotype [62]. The PLOD1 gene is a
strong functional candidate for BMD regulation as it encodes
Procollagen-lysine, 2-oxoglutarate, 5-dioxegenase, which catalyses
the hydroxylation of lysine residues during the posttranslational
modiﬁcation of type I collagen. In a population-based study of women
from the UK, Tasker et al. [65] reported a signiﬁcant association
between LS BMD and the G386A polymorphism, which results in an
alanine–threonine amino acid change at codon 99. Heterozygotes for
G386A had signiﬁcantly reduced LS BMD when compared with the
other genotype groups. Association analysis between nucleotide
variations of the BNP gene and radial BMD in 378 Japanese
postmenopausal women revealed a signiﬁcant association of the
−381T/C SNP in the promoter region of BNP gene with radial BMD.
BMD was lowest in T/T homozygotes, intermediate among hetero-
zygotes, and highest among C/C homozygotes in the test population.
Accelerated bone loss also correlated with the −381 T allele in a 5-
year follow-up study, suggesting that variation of BNP may be an
important determinant of postmenopausal osteoporosis [66].
Chromosome 5
Bmd2 is the only BMD QTL mapped at Chromosome 5 (Table 1)
[13,14]. Seven BMDAP genes are found and Bmd2 includes four ofthem: (1) Kit, (2) Cd38, (3) aldehyde dehydrogenase (Aldh2), and (4)
sulfotransferase 1E1 (Sult1e1). KIT plays an important role in the
differentiation of osteoclasts. Kim et al. [73] examined the associations
betweenKITgenepolymorphisms and BMD inpostmenopausal Korean
women. Haplotype analyses showed that the ht3 haplotype (−1694T–
+41894A–+49512G) was signiﬁcantly associated with lower BMD at
femoral neck. Drummond et al. [74] demonstrated that the CD38-PvuII
polymorphism was signiﬁcantly associated with LS BMD in pre- and
postmenopausal women. The CD38-PvuII polymorphism was also
signiﬁcantly associated with FN BMD in the premenopausal cohort.
The G allele at this locus appears to be a risk allele for low BMD. CD38
knockout mice also displayed signiﬁcantly decreased BMD at all
skeletal sites at 3 months of age compared to those wild-type mice.
ALDH2 Glu487Lys polymorphism has been strongly associated with
osteoporosis. The risk of reduced bonemasswas signiﬁcantly higher in
the group having the Lys/Lys genotype than in the group having the
Glu/Lys or Glu/Glu genotype. This suggests that possession of Glu
allele may be protective against osteoporosis [75]. In a community-
based cross-sectional studyconducted on397Koreanwomen, Lee et al.
[76] found that BMD in the calcaneus was inﬂuenced by the genetic
polymorphism of SULT1E1⁎959 GNA and phytoestrogen consumption.
In addition, the association between phytoestrogen consumption and
calcaneal BMD might be modiﬁed by genetic polymorphism of
SULT1E1. Women with the SULT1E1⁎959 GG genotype had a lower
BMD at the distal radius and calcaneus compared to those with the AA
genotype, especially at the calcaneus in premenopausal women.
Three BMDAP genes are located outside of QTL region. Interleukin-
6 (IL6) is a well-known factor affecting BMD. In 470 Japanese subjects,
Ota et al. [183] found a correlation between the presence of the G
allele of a C/G polymorphism at nucleotide −634 in the promoter
region and decreased BMD. BMD was lowest among the GG
homozygotes, highest among the CC homozygotes, and intermediate
among the heterozygotes. Chung et al. [184] also described a SNP IL6-
572 G→C in the IL6 promoter region that showed signiﬁcant
association with BMD. The C allele was associated with increased
BMD in a gene-dose-dependent manner in premenopausal women.
Kawano et al. [185] examined the relationship between the three
common SNPs of klotho (KL) gene and BMD in white women and
Japanese postmenopausal women. In the white population, one in the
promoter region (G-395A) and one in exon 4 (C1818T) and their
haplotypes were signiﬁcantly associated with bone density in aged
postmenopausal women (≥65 years), but not in premenopausal or
younger postmenopausal women. These associations were also seen
in Japanese postmenopausal women. These results indicate that the
KL gene may be involved in the pathophysiology of bone loss with
aging in humans. In a population-based prospective cohort study of
aging and age-related diseases, Yamada et al. [186] conﬁrmed the
association of −395G→A polymorphism with BMD in Japanese
women. LS BMD was signiﬁcantly lower in subjects with the GG
genotype than in those with the AA genotype. Koh et al. [187] found
that the minor allele of FLT3+13348CNT, an intronic polymorphism
in FMS-related tyrosine kinase 3 (FLT3), was signiﬁcantly associated
with low LS BMD and FN BMD. Haplotype analysis revealed that FLT3-
ht2 (TTCTT) containing the rare allele in the +13348 position also
showed signiﬁcant association with low BMD at both sites.
Chromosome 6
Chromosome 6 contains three BMD QTL (Table 1) [13,21,27,46].
Seven BMDAP genes are identiﬁed. Among them, four are within QTL
region, which are microphthalmia-associated transcription factor
(Mitf), peroxisome proliferator-activated receptor gamma (Pparg),
vitamin-K-dependent gamma-glutamyl carboxylase (Ggcx), and
matrix Gla protein gene (Mgp). MITF plays a critical role in osteoclast
development and thus is an important candidate gene affecting BMD.
Koh et al. [83] found that two polymorphsms, MITF+227719CNT,
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associated with the BMD of the proximal femur in postmenopausal
women. The MITF+227719CNT polymorphism was signiﬁcantly
associated with low BMD of the trochanter and total femur. The
effects of MITF+227719CNTon the BMD of the trochanter were gene-
dose dependent; the highest BMD being found in homozygotes for the
common allele, intermediate BMD in heterozygotes, and the lowest
BMD in homozygotes for the rare allele. Moreover, the MITF+
228953ANG polymorphism was also associated with low BMD of the
femoral shaft. Homozygotes for the G allele had lower BMD at the
femoral shaft compared with those without either G allele. The MITF-
ht3 haplotype was associated with low BMD of the trochanter and
total femur. These results suggest thatMITF variants may play a role in
the decreased BMD of the proximal femur in postmenopausal women.
Three BMDAP genes outside of QTL region are collagen type I
alpha2 (Col1a2), neuropeptide Y (Npy), and calcitonin receptor (Calcr).
Chromosome 7
Chromosome 7 contains ﬁve BMD QTL (Table 1) [21,27,32,42,46]
and six BMDAP genes. Among them, transforming growth factor beta 1
gene (Tgfb1), perilipin (Plin), and apolipoprotein E (Apoe) are within
QTL region. The 1243C→T polymorphism of PLIN has been associated
with BMD for the total body, lumbar spine, femoral neck, and
trochanter inmen, with the C allele being related to reduced BMD [92].
Three BMDAP genes in non-QTL region are: (1) osteoclast-
associated receptor (Oscar), (2) dopamine receptor D4 gene (Drd4),
and (3) parathyroid hormone (Pth). A polymorphism OSCAR −2322
ANG in the 5′ ﬂanking region of OSCAR gene might be one of genetic
determinants of BMD. OSCAR −2322 ANG was associated with BMD
at both the lumbar spine and femoral neck. At the lumbar spine, the
genetic effects of OSCAR −2322 ANG on BMD were gene-dose
dependent, and the highest BMD was found in homozygotes for the
common allele. However, at the femoral neck, the OSCAR−2322 ANG
showed dominant effect on BMD values; a higher BMD was found in
individuals bearing the GG genotype than in others (AA and AG
genotypes). The genetic effects of OSCAR −2322 ANG on BMD were
also detected at other femoral sites [188]. DRD4 may be a candidate
locus for reduced BMD in men. The−521C→T SNP of DRD4 has been
signiﬁcantly associated with BMD at various sites in Japanese men.
The C allele appears to be acting as a risk allele for low BMD [189].
Chromosome 8
There is no BMD QTL mapped into Chromosome 8. One BMDAP
gene is identiﬁed. The −512C→T polymorphism of forkhead box C2
(FOXC2) has been associated with BMD for the distal and proximal
radius in men and in premenopausal women as well as with BMD for
the distal radius and total body in postmenopausal women, with the T
allele representing a risk factor for reduced BMD [92].
Chromosome 9
Three BMD QTL are located on Chromosome 9.We identiﬁed seven
BMDAP genes for this chromosome. Among them, four are within QTL
region, including: (1) cytochrome P450, family1, subfamily A,
polypeptide 1 (Cyp1a1), (2) semaphorin 7a (Sema7a), (3) lipase,
hepatic (Lipc), and (4) intercellular adhesion molecule 1 (Icam1).
Estrogen metabolism is an important determinant of bone mass [101].
The C4887A polymorphism of CYP1A1 gene, one of the key enzymes
that metabolize estrogen, has been associated with BMD. C→A
transversion, which results in an amino acid change from threonine to
asparagine at codon 461, was identiﬁed as a possible genetic risk factor
for low BMD. The reduced BMD as well as consequently the risk of
osteoporosis associated with this polymorphism may be a result of
accelerated estrogen catabolism and increased bone resorption [100].In addition, several polymorphisms of cytochrome P450, family19,
subfamily A, polypeptide 1 (CYP19A1) gene, an enzyme involved in
estrogen synthesis, have also been associated with BMD [190,191].
Among them, a polymorphism Aro1 (rs4775936), located in a
promoter region of CYP19A1, has been associated with LS BMD in
postmenopausal women. Homozygotes AA exhibited signiﬁcantly
higher LS BMD, compared with GG or GA individuals [190].
The (AAAG)n polymorphism in the P3 promoter of the parathyroid
hormone type 1 receptor (PTHR1) gene has been associated with BMD
in Caucasian women. The subjects bearing at least one (AAAG)6 allele
have a higher FN BMD than those without, suggesting the variation in
promoter activity of the PTHR1 gene may exert a relevant genetic
inﬂuence on BMD [33]. In addition, the 190G→A (Val64Ile)
polymorphism of CC chemokine receptor-2 (CCR2) has been asso-
ciated with BMD at various sites in community-dwelling, middle-aged
Japanese men and postmenopausal women, and that the AA genotype
represents a contributing factor to increased bone mass [192].
Chromosome 10
Chromosome 10 contains two BMD QTL (Table 1) [27,107] and two
BMDAP genes. Among them, insulin-like growth factor I (Igf1) is
located in QTL region. In a large population-based study of elderlymen
and women, Rivadeneira et al. reported that the absence of the wild-
type (192-bp) allele in a (CA)n repeat polymorphism in the promoter
region of the IGF1 gene is associated with lower BMD levels and
higher rates of bone loss at the different femoral sites in women.
However, no associations were observed in men at any femoral site of
BMD measurement [108].
Estrogen and the estrogen receptor 1 (ESR1, also named ER) play a
central role in bone metabolism. The relationship between the
polymorphisms associated with the ESR1 gene and BMD and osteo-
porotic fracture has been extensively investigated. The (TA)(n)
dinucleotide repeat polymorphism at the 5′ end of the ESR1 gene has
been associated with BMD. Subjects with a low number of repeats
(TAb15) showing the lowest BMD values and increased fracture risk
[193,194]. In addition, a newly identiﬁed CA repeat polymorphism of
ESR1 has been associatedwith BMD variation. The number of CA repeats
was linearly related to hip BMD in postmenopausal women. Post-
menopausal women with CA repeats b18 had higher risks of having
osteoporosis and low trauma fractures than thosewith≥Theoperator(/
=waschangedtoŒhere.Pleasecheckifappropriate.–>18 repeats. Peri-
menopausal womenwith b18 CA repeats had signiﬁcantly greater bone
loss in 18 months at the hip than those with ≥18 repeats [195].
Chromosome 11
Seven BMD QTL are mapped on Chromosome 11 (Table 1)
[13,21,30–32,42,131]. A total of 8 BMDAP genes are identiﬁed: (1)
arachidonate 15-lipoxygenase (Alox15), (2) arachidonate 12-lipox-
ygenase (Alox12), (3) PDZ-LIM domain protein 4 (Pdlim4, also named
Ril), (4) growth hormone (Gh, also named Gh1), (5) sex hormone-
binding globulin (Shbg), (6) collagen type I alpha 1 (Col1a1), (7)
angiotensin converting enzyme (Ace), and (8) sclerosteosis/van
Buchem disease gene (Sost). All of these genes are located within
QTL region. Through combined genetic and genomic approaches, Klein
et al. [9] identiﬁed Alox15 as a negative regulator of peak bonemineral
density in mice. This gene was also considered as the causal gene
underlying a BMD QTL peaked at D11Mit349. There are three
lipoxygenases in humans, ALOX15, ALOX15B, and ALOX12, that
correspond to 12/15-lipoxygenase in mice. A SNP −5299G/A in
ALOX15 5′-ﬂanking region, has been associated with BMD in
postmenopausal Japanese women. Subjects with the A allele had
signiﬁcantly lower LS BMD and total body BMD [114]. Interestingly,
Ichikawa et al. [115] tested genetic association of ALOX12 and ALOX15
with BMD variation in a large cohort of healthy American white men
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ALOX15, are signiﬁcantly associated with spine BMD in white men
and women. In adult Japanese women, Omasu et al. [117] found an
association between the T allele in the −3333T–C polymorphism in
the 5-prime ﬂanking region of the PDLIM4 gene to low bone mineral
density (BMD) in an allele-dosage-related manner. This variation may
also be an important determinant of osteoporosis. Polymorphisms at
COL1A1 and TGFB1 and haplotypes at COL1A1 and ESR1 were found
to be associated with BMD in a cohort of postmenopausal Spanish
women. Moreover, COL1A1 polymorphisms showed signiﬁcant inter-
actions among them and with the VDR 3′ polymorphisms [93]. Pérez-
Castrillón et al. [123] assessed the relationship between bone mineral
density and insertion/deletion (I/D) ACE polymorphism in hyperten-
sive postmenopausal women. They found that women with II
genotype showed a higher intact parathyroid hormone without a
decrease in calciuria, and higher bone mineral density than women
with ID and homozygotus deletion genotype, suggesting the ACE
polymorphism could be one of the factors causing bone mass
variations. Two variants, SRP3 and SRP9, in the SOST region have
been associated with BMD variation. SRP3 was associated with
decreased BMD in women at the LS and FN, with evidence of an
allele-dose effect in the oldest age group. Similarly, a G variant SRP9
was associated with increased BMD in men at the LS and FN [124].
Chromosome 12
Chromosome 12 contains two BMD QTL (Table 1) [21,31]. Two
BMDAP genes are identiﬁed. Both of them are located within QTL
region. Several SNPs of estrogen receptor beta (ESR2) gene have been
associated with BMD. The C allele of T-1213C was associated with
lower BMD and a 2–3-fold increased risk of osteoporosis in both men
and women, while the G allele of A110732G was associated with
higher BMD and a 40% reduction in risk of osteoporosis at the spine in
postmenopausal women. Besides, C-1018T was associated with
signiﬁcant reduction in risk of osteoporosis at the hip in premeno-
pausal women. Among all SNPs, T-1213C was the most signiﬁcant
predictor of BMD, risk of osteoporosis and osteoporotic fractures
[132]. Thyroid stimulating hormone (TSH) inhibits, through the TSH
receptor (TSHR), both osteoclastic bone resorption and osteoblastic
bone formation. TSHR knockout mice display high-turnover osteo-
porosis [135]. In the Rotterdam Study, van der Deure et al. [134] found
that a common polymorphism TSHR-Asp727Glu in TSHR gene was
dose-dependently associated with higher FN BMD. Carriers of the Glu
allele had a higher FN BMD than noncarriers.
Chromosome 13
Chromosome 13 contains four BMD QTL (Table 1) [13,14,21,42,131]
and ﬁve BMDAP genes. The BMDAP genes are: (1) secreted frizzled-
related protein (Sfrp4), (2) hemochromatosis gene (Hfe), (3)_receptor
tyrosine kinase-like orphan receptor 2 (Ror2), (4) integrinalpha1
(Itga1), and (5) phosphodiesterase 4D (Pde4d). Among them, Sfrp4,
Hfe, and Ror2 are within QTL region. Sfrp4 has been identiﬁed as the
responsible gene of QTL Pbd2 affecting peak BMD in SAMP6mice [10].
The syntenic region of this locus corresponds to human-7p14, which
has also been detected as a QTL for BMD [136,137]. These evidences
suggest the possibility that a common susceptibility gene for human
and mouse peak BMD is present in this location, and a polymorphism
of Sfrp4 may contribute to the variation in human peak BMD.
Lee et al. [196] analyzed eight SNPs in integrinalpha1 (ITGA1)
region for their potential involvement in osteoporosis in postmeno-
pausal women. The SNPs, +73187CNT and +76969TNG, and their
haplotypes BL_hts were associated with BMD at various femur sites.
Moreover, +159174ANC and its haplotype BL3_ht1 showed a highly
signiﬁcant association with risk of non-vertebral fracture and the
minor allele of +159174ANC showed a protective effect. These resultsare suggestive of the association of ITGA1 with osteoporosis and
related risk in postmenopausal women.
Chromosome 14
Five BMD QTL are located on Chromosome 14 (Table 1)
[13,21,31,32,72]. Two BMDAP genes are receptor activator of NF-
kappa B ligand (Rankl, also named Tnfsf11) and bone morphogenetic
protein 4 (Bmp4). Only Tnfsf11 is within QTL region. Three key genes in
a bone remodeling pathway, RANKL, receptor activator of NF-kappa B
(RANK, also named TNFRSF11A), and osteoprotegerin (OPG, also named
TNFRSF11B) were assessed for their genetic contribution to BMD
variation. Signiﬁcantly positive associations were found for A163G
polymorphisms in the promoter regions of the OPG gene, a missense
substitution in exon 7 (Ala192-Val) of the RANK gene and rs9594782
SNP in the 5′ UTR of the RANKL gene with BMD in men only. Menwith
TC/CC genotypes of the rs9594782 SNP had a 2.1 times higher risk of
extremely low hip BMD, and lowerwhole body BMD. Subjectswith the
TC genotype of the Ala192Val polymorphism had a 40% reduced risk of
having extremely low hip BMD, and higher whole body BMD. Subjects
with the GG genotype of the A163G polymorphism had a 70% reduced
risk of having extremely low hip BMD, and higher whole body BMD.
Signiﬁcant gene–gene interactionswere also observed among theOPG,
RANK and RANKL genes. These ﬁndings suggest that genetic variation
in genes involved in the RANKL/RANK/OPG bone remodeling pathway
are strongly associated with BMD at different skeletal sites in adult
men, but not in women [142]. Another report also indicated that the
−290CNT polymorphism in the TNFSF11 gene promoter could
contribute to the genetic regulation of BMD [143].
A polymorphism 6007CNT in the BMP4 gene has been associated
with hip bone density in postmenopausal women. This polymorphism
codes for a nonsynonymous amino acid change with the T allele
coding for valine, while the C allele codes for alanine. BMD was lower
in the 32% of subjects homozygous for the C allele. In addition, a major
haplotype deﬁned by G-C-T alleles in SNPs 5826GNA, 3564CNT and
6007CNT respectively, showed associationwith high bone mass [197].
Chromosome 15
Chromosome 15 conta ins s ix BMD QTL (Table 1)
[13,14,31,32,46,107]. Three BMDAP genes were found and QTL region
covers all of them. Studies on the role of polymorphisms in the vitamin
D receptor (VDR) gene in the determination of bone mineral density
have been conﬂicting. Among a group of prepubertal American girls of
Mexican descent, Sainz et al. [158] found that girls with the aa and bb
genotypes had 2 to 3% higher femoral bone density and an 8 to 10%
higher vertebral bone density than girls with AA and BB genotypes.
Horst-Sikorska et al. [159] also observed a statistically signiﬁcant
association of the VDR gene polymorphisms and haplotypes with the
BMD and with the occurrence of fractures. However, several other
studies found no association between VDR genotype and BMD
[160,161]. A novel heterozygous acceptor splice site mutation of
exostoses 1 (EXT1) results in hereditary multiple exostosis (HME) that
is associatedwith a lowpeakbonemass, indicating a possible additional
role for EXT1 in bone biology and in regulating BMD [153]. In addition,
the A163G polymorphisms in the promoter regions of the TNFRSF11B
gene have also been associated with BMD [142].
Chromosome 16
Four BMD QTL were identiﬁed on Chromosome 16 (Table 1)
[21,32,42]. QTL region covers all three BMDAP genes including
calcium-sensing receptor (Casr), catechol-O-methyltransferase
(Comt), and alpha2-HS glycoprotein (Ahsg). Tsukamoto et al. [163]
investigated the association between the CA-repeat polymorphism
at the human CASR gene locus and BMD of radial bone in
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signiﬁcantly lower adjusted BMD than the participants who did not
carry an allele of that size. This result suggests that genetic variation at
the CASR gene locus is associated with some determinants for BMD in
postmenopausal women. In addition, a functional polymorphism
val158met in COMT gene has been associated with peak BMD in men
[166]. AHSG gene polymorphisms are also associated with BMD in
Caucasian nuclear families [164].
Chromosome 17
Two BMD QTL are located on Chromosome 17 (Table 1) [31]. We
found four BMDAP genes, among them, tumor necrosis factor (Tnf),
runt related transcription factor 2 (Runx2), and chloride channel 7
(Clcn7) are within QTL region. Two polymorphisms TNF-alpha-863C/
A and the -1031T/C of the TNF gene have shown linkage with the LS
BMD in early postmenopausal Japanese women. There was a
signiﬁcantly higher prevalence of the alleles TNF-alpha-863A and
TNF-alpha-1031C in women with the low BMD than women with the
high BMD [168]. RUNX2 is a master regulator of osteoblast function.
RUNX2 contains a glutamine–alanine repeat. Two common variants
were detected within the alanine repeat: an 18-bp deletion and a
synonymous alanine codon polymorphism with alleles GCA and GCG
(noted as A and G alleles, respectively). In addition, rare mutations
that may be related to low BMD were observed within the glutamine
repeat. In 495 randomly selected women of the Geelong Osteoporosis
Study (GOS), the A allele was associated with higher BMD at all sites
tested. The effect was maximal at the ultradistal radius. In a separate
fracture study, the A allele was signiﬁcantly protective against Colles'
fracture in elderly women but not spine and hip fracture. The A allele
was associated with increased BMD and was protective against a
common form of osteoporotic fracture, suggesting that RUNX2
variants may be related to genetic effects on BMD and osteoporosis
[170]. In addition, −1025 T/C polymorphism in the promoter 2 of
RUNX2 gene has been associated with FN BMD in Spanish post-
menopausal women [171].
QPCT is located outside of QTL region. However, multiple SNPs in
QPCT revealed signiﬁcant association with forearm aBMD among
adult women from the general population in Japan. Most of these
variations were potentially functional, speciﬁcally a nonsynonymous
coding SNP, R54W (rs2255991), and several SNPs that seemed to be
in promoter sequences [198]. The human QPCT gene lies on
chromosome 2p22.3, within the region where a QTL for forearm
BMD has been identiﬁed in the Chinese population [199] and near a
QTL for spinal BMD identiﬁed among whites [200]. Huang et al.
performed a gene-wide and tag single nucleotide polymorphism
(SNP)-based association study of four positional and functional
candidate genes. The rs3770748 within the QPCT gene showed a
signiﬁcant association with spine BMD in both singlemarker and
haplotype association analyses. Subgroup analysis revealed that the
effect was primarily driven by an association in the postmenopausal
women, presumably suggesting that the rs3770748 affects post-
menopausal bone loss rather than peak bone mass. These results
suggest that QPCT may be the QTL gene at chromosome 2p for spine
BMD variation in the Chinese population [11].
Chromosome 18
Although threeBMDQTLweremapped on Chromosome18 (Table 1)
[13,21,31,32], no BMDAP gene was found. Some genes responsible for
BMD variation may not yet be identiﬁed on this chromosome.
Chromosome 19
One QTL was mapped on Chromosome 19 (Table 1) [32]. Five
BMDAP genes were identiﬁed. Only one BMDAP gene, cytochromeP450, family 17, subfamily A, polypeptide 1 (Cyp17a1) is located in QTL
region. Yamada et al. [179] examined the associations of BMD with
three polymorphisms, the −34T→C polymorphism of CYP17A1, the
−493G→T polymorphism of microsomal triglyceride transfer pro-
tein gene (MTTP), and a CGG repeat polymorphism of the very low
density lipoprotein receptor gene (VLDLR). The−34T→C polymorph-
ism of CYP17A1 and the CGG repeat polymorphism of VLDLR have
been associated with BMD in postmenopausal women and in men,
respectively.
Multiple investigations have reported the associations between
BMD and polymorphisms and/or haplotypes in the low-density
lipoprotein receptor-related protein 5 (LRP5) gene. Mizuguchi et al.
[201] performed an association study between BMD and 9 candidate
genes in Japanese women. They found that only LRP5 showed a
signiﬁcant association with BMD. A follow-up case-control study
revealed a signiﬁcant difference in allelic frequency of the LRP5
c.2220CNT SNP. The T allele was more frequently deposited in
patients than in normal control women. The authors suggested that
LRP5 is a BMD determinant and contributes to a risk of osteoporosis.
The results from other studies also supported this standpoint [202–
204]. Allelic variation at the G-1102A polymorphism in the promoter
of T cell immune regulator 1 (TCIRG1) gene has been associated with
BMD in premenopausal women of Scottish descent. This polymorph-
ism is situated at a consensus recognition sequence for the
transcription factor AP1. In the presence of the G-nucleotide, a
consensus AP1 site is present on the reverse strand (TCACGGC)
whereas in the presence of the A nucleotide, the consensus sequence
is altered (TCATGGC). Homozygotes for G allele had BMD values
signiﬁcantly higher than individuals who carried the A allele [205]. A
statistically signiﬁcant association between LS BMD of white
premenopausal women and a regulatory variant in the estrogen-
related receptor alpha (ESRRA) promoter has been observed. Women
with long variants showed a higher LS BMD than those with common
short variants. The same trend was observed for FN BMD. These
results support the genetic inﬂuence of this ESRRA regulatory variant
on BMD [206].
Chromosome X
Chromosome X carries only one QTL (Table 1) [181]. Two
BMDAP genes are found. However, neither of them is located in QTL
region. Androgen receptor (AR) gene was reported to be a
determinant of BMD in premenopausal Japanese women, with the
(CAG)(n≥23) allele of a CAG repeat polymorphism representing a
risk factor for reduced BMD [186]. The haplotype 196F/532S
constructed from two amino acid-substituting SNPs in the inter-
leukin-1-associated kinase 1 (IRAK1) gene has been signiﬁcantly
associated with decreased radial BMD. Radial bone mineral density
was lowest among 196F/532S homozygotes, highest among 196S/
532L homozygotes, and intermediate among heterozygotes. Accel-
erated bone loss also correlated with the 196F/532S haplotype in a
5-year follow-up. These results suggest that variation of IRAK1 may
be an important determinant of postmenopausal osteoporosis, in
part through the mechanism of accelerated postmenopausal bone
loss [207].
Chromosome Y
Neither BMDQTL nor BMDAP gene are identiﬁed on Chromosome Y.
Conclusions
We performed a whole genome scan to identify QTL, genes,
polymorphisms that determine BMD.We found that a large number of
BMD QTL have been identiﬁed in mouse models. However, direct
determination of causal genetic factors (i.e. genes) within the BMD
410 Q. Xiong et al. / Genomics 93 (2009) 401–414QTL regions has been slow and remains a major bottleneck in fully
understanding the genetic mechanism underlying BMD variation. To
our knowledge, only four genes were identiﬁed as responsible for
BMD QTL [8–11]. With advances in genetics and genomics, an
enormous amount of data related to gene function has been
accumulated in some large publicly accessible databases. By gen-
ome-wide analysis of genes and polymorphisms involved in regula-
tion of BMD using the currently available data in PubMed, OMIM,
Mammalian Phenotype Ontology, and Gene Ontology, we found that
many genes have been shown to be associated with BMD, most of
which were identiﬁed from association studies in human subjects.
These genes are important candidates that may be responsible for the
QTL effects and should be carefully investigated in direct experiments
to precisely establish their functional roles. Evidence from functional
assessment (e.g. from knockouts or transgenics), gene expression
proﬁling, and SNP analyses will be necessary to conﬁrm the actual
involvement of these genes in BMD regulation and measure the
degree of their contribution to BMD.
Based on our in silico analysis, most QTL include more than one
BMDA/BMDAP gene. One possibility is that those QTL include several
linked sub-loci and therefore are caused by a series of genes, eachwith
a small effect. This possibility is demonstrated by QTL Bmd5, which
has been subdivided into three linked loci by two independent
investigations [26,29]. Of course, we cannot rule out that some QTL
may be caused by a major gene with large effect. It is also possible that
some BMDA/BMDAP genes identiﬁed in human population may not
be a functional contributor to BMD variation in mouse. Another
possibility is that some BMDA/BMDAP genes may have no actual
contribution to BMD variation under the conditions for the measure-
ment of BMD QTL since we didn't evaluate the QTL or genes in a site-,
gender-, age-, strain- or population-speciﬁc manner. Convincing
evidences have shown that the QTL or genes which regulate BMD
have site-, gender-, age-, strain-, or population-speciﬁc effects
[21,26,137], accordingly, those candidate genes should be evaluated
and tested separately. Although our data provide a starting point for
such a test, experiments would have to be conducted to test those
candidate genes.
Therewere noQTL detected on Chromosome8 although the obvious
candidate genes exist. In addition, for someQTL, no BMDA/BMDAP gene
was identiﬁed, and some chromosomes include fewer BMDA/BMDAP
genes in QTL regions than in non-QTL regions. This complexity may be
explained by several possibilities: 1)methods adopted for QTLmapping
cannot detect all QTL, especially some small-effect QTL, because of small
sample size, small phenotypic variance, sparse marker coverage, etc; 2)
genome annotation is not complete. some unknown BMDA/BMDAP
genes may exist in QTL regions and/or non-QTL regions since direct
effects on BMD regulationmay not yet be recognized formany genes; 3)
some BMDA/BMDAP genes identiﬁed from human or other speciesmay
have no effect on BMD regulation in mouse because the same gene or
polymorphismmay have different inﬂuences on the same phenotype in
different species or ethnic groups; 4) Among 83 BMDAP genes, only 4
came frommouse studies.Most of BMDAP geneswere selected based on
association studies in humans linking a polymorphism with lower (or
higher) BMD. Few of these polymorphisms have been conﬁrmed as
causal. It is thus possible that it is not the gene named, but an adjacent
gene that contains the causal polymorphism. Of course, there is a good
chance that adjacent genes are syntenic in mouse. Finally, our methods
will not identify new genes.
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